Randomised clinical trial: Design of the SYNERGY‐NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction‐associated steatohepatitis and modification of screening strategy to reduce screen failures

Post time 2024-6-14 08:02:24

journal：Alimentary Pharmacology & Therapeutics

Authors：Raj Vuppalanchi; Rohit Loomba; Arun J. Sanyal; Amir Nikooie; Yuanyuan Tang; Deborah A. Robins; Bram Brouwers; Mark L. Hartman

Published date：2024-7-

DOI：10.1111/apt.18042

PDF link：https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/apt.18042

Article link：http://dx.doi.org/10.1111/apt.18042

Article Source：Wiley。

Remark：

Post time 2024-6-14 08:02:25

: This post has been completed
Completed attachments will be deleted within 24 hours.

[Wiley] Randomised clinical trial: Design of the SYNERGY‐NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction‐associated steatohepatitis and modification of screening strategy to reduce screen failures

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Wiley] Randomised clinical trial: Design of the SYNERGY‐NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction‐associated steatohepatitis and modification of screening strategy to reduce screen failures Copy

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today

[Wiley] Randomised clinical trial: Design of the SYNERGY‐NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction‐associated steatohepatitis and modification of screening strategy to reduce screen failures